How Does Somatostatin Work? Mechanism of Action in the Published Research

Somatostatin is best described in the literature as an inhibitory signalling peptide: rather than switching a process on, it dampens secretion and excitability in the tissues where its receptors are expressed. A 2020 review of the regulatory mechanisms of somatostatin expression described the peptide as being produced from a precursor, preprosomatostatin, and processed into the two bioactive forms somatostatin-14 and somatostatin-28, which are released from hypothalamic neurons, pancreatic delta cells, gastrointestinal endocrine cells and other sites (PMID 32545257). This page summarises what published pharmacology reports about receptor targets, intracellular signalling and downstream physiology, and marks clearly where findings came from cell or animal models. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a hormone, medicine or health condition.

The Receptor Targets: SSTR1 Through SSTR5

The established starting point of somatostatin's mechanism is a family of five receptors. A review of pituitary somatostatin receptor signalling described SSTR1 to SSTR5 as seven-transmembrane G protein-coupled receptors that couple predominantly to inhibitory G proteins (Gi/Go), with SSTR2 and SSTR5 the subtypes most relevant to growth hormone-secreting pituitary cells (PMID 20149677). A 2018 review of somatostatin receptors in the brain reported that the subtypes are distributed unevenly across cortical, hippocampal and subcortical regions, so the same peptide can produce different local effects depending on which receptor is present (PMID 30656906).

Native somatostatin binds all five subtypes with broadly comparable affinity, which reviews of somatostatin and somatostatin receptors in tumour biology described as one reason the natural peptide produces wide-ranging inhibitory effects, while synthetic analogues were developed with narrower subtype preferences (PMID 38203605). Receptor subtypes have also been reported to form homodimers and heterodimers and to interact with other G protein-coupled receptors, a feature reviewed in the context of neuroendocrine tumour signalling (PMID 35163374).

What Happens Inside the Cell

Once somatostatin occupies its receptor, published pharmacology describes a set of overlapping intracellular consequences rather than a single switch. The review of pituitary somatostatin receptor signalling reported that receptor activation inhibits adenylyl cyclase and lowers cyclic AMP, activates inwardly rectifying potassium channels, and reduces voltage-gated calcium channel activity, with the net effect of hyperpolarising the cell and limiting the calcium influx that secretory granules require (PMID 20149677). That same review described additional, cAMP-independent routes acting more directly on the secretory machinery (PMID 20149677).

Beyond the acute inhibition of secretion, reviews of somatostatin receptors in tumour biology described recruitment of protein tyrosine phosphatases such as SHP-1 and SHP-2 and modulation of mitogen-activated protein kinase cascades, which researchers have linked to antiproliferative signalling in receptor-expressing cells (PMID 38203605). A review of somatostatin signalling in neuroendocrine tumours similarly reported receptor-mediated effects on cell cycle regulators and on apoptotic pathways, alongside receptor internalisation and trafficking as determinants of how long a signal persists (PMID 35163374).

1. Binding: somatostatin engages one or more of SSTR1-5 on the target cell surface (PMID 20149677).
2. G protein coupling: inhibitory G proteins reduce adenylyl cyclase activity and cyclic AMP (PMID 20149677).
3. Ion channel effects: potassium conductance rises and calcium entry falls, reducing excitability and exocytosis (PMID 20149677).
4. Phosphatase and kinase signalling: SHP phosphatases and MAPK pathways are engaged, which reviews connect to growth-inhibitory effects in receptor-positive cells (PMID 38203605).
5. Receptor regulation: internalisation, recycling and expression changes shape the duration and strength of the response (PMID 35163374).

Downstream Physiology Described in the Literature

Pituitary and growth hormone

Somatostatin was originally characterised as the hypothalamic factor that restrains growth hormone release, and a review of pituitary somatostatin receptor signalling described SSTR2 and SSTR5 activation as the principal route by which somatotroph secretion is suppressed (PMID 20149677). A review of growth hormone secretagogue development described somatostatin as the inhibitory arm of a system whose stimulatory arm includes growth hormone-releasing hormone and ghrelin-like secretagogues, with pulsatile growth hormone output emerging from the interplay between them (PMID 15814848).

Work on pituitary tumours has examined why that inhibitory brake works better in some tumours than others. A 2017 review of AIP and the somatostatin system in pituitary tumours reported that the aryl hydrocarbon receptor-interacting protein influences somatostatin receptor expression and signalling, offering a molecular explanation for differences in responsiveness between tumours (PMID 28835453).

Gastrointestinal tract and pancreas

The 2020 review of somatostatin expression described delta cells in the pancreatic islets and endocrine cells in the gut as major peripheral sources, with somatostatin acting locally in a paracrine fashion to restrain neighbouring secretory cells (PMID 32545257). That review also reported that somatostatin gene expression is itself tightly regulated by transcription factors and nutrient- and hormone-related signals, meaning the inhibitory tone varies with physiological context (PMID 32545257).

Central nervous system

In the brain, somatostatin functions less as a circulating hormone and more as a neuromodulator. A 2022 review of somatostatin and somatostatin-containing interneurons described these interneurons as a major inhibitory population that shapes cortical and hippocampal circuit activity and synaptic plasticity, and reported that alterations in this population have been observed in a range of neurological and psychiatric conditions (PMID 35204812). The 2018 review of brain somatostatin receptors reported subtype-specific roles in neuronal signalling consistent with the receptors' uneven regional distribution (PMID 30656906).

Established Mechanism Versus Proposed Mechanism

It helps to separate what is consistently described across pharmacology reviews from what remains an interpretation drawn from models.

• Well characterised: binding to five G protein-coupled receptors with inhibitory coupling, reduced cyclic AMP, altered potassium and calcium conductance, and suppression of hormone secretion in pituitary and islet cells (PMID 20149677).
• Well characterised: receptor overexpression on many neuroendocrine tumours, which is the physical basis for receptor-targeted imaging and radioligand approaches (PMID 38203605).
• Partly established: antiproliferative signalling through phosphatases, cell cycle regulators and apoptosis, much of it mapped in cell lines and reviewed in the neuroendocrine tumour literature (PMID 35163374).
• Proposed and under study: the extent to which somatostatin interneuron dysfunction causes, rather than accompanies, specific brain pathologies, a question the 2022 interneuron review framed as still open (PMID 35204812).

Mechanism as a Targeting Strategy

Because receptor density is high on many neuroendocrine tumours, the somatostatin system has been exploited not only to inhibit secretion but to deliver payloads. A 2019 review of ¹⁷⁷Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumours described peptide receptor radionuclide therapy as using a somatostatin analogue to carry a radioisotope to SSTR-expressing tumour cells, with receptor binding and internalisation central to how the agent reaches its target (PMID 31652074). A 2022 review of resistance mechanisms in gastroenteropancreatic neuroendocrine tumours reported that loss or downregulation of somatostatin receptor expression, along with other tumour-cell adaptations, is among the factors researchers have linked to reduced responsiveness over time (PMID 36551599).

Preclinical and Animal Work: How to Read It

A substantial part of the mechanistic literature on neuropeptides comes from rodent models, and findings there describe the model, not people. A 2024 study of neuropeptide therapeutics reported that repressing lateral septum neurons that disable sociability altered social behaviour in an autism mouse model, illustrating how neuropeptide signalling at defined circuit nodes can shift behaviour in animals (PMID 39423809). Separately, a 2025 mouse study reported that reduced oxytocin signalling in the dorsal bed nucleus of the stria terminalis drove a transition from acute pain to persistent anxiety, an example of how a single neuropeptide pathway in one nucleus can be mapped onto a behavioural state in rodents (PMID 41015042). Neither animal finding establishes a human effect; they are included here to show the kind of circuit-level evidence that informs proposed, rather than established, neuropeptide mechanisms.

Tolerability and Limitations in the Mechanistic Literature: What Studies Report

The reviews cited on this page are mechanistic and clinical overviews rather than safety trials, and most do not catalogue adverse events in detail. The review of ¹⁷⁷Lu-DOTATATE in gastroenteropancreatic neuroendocrine tumours discussed the clinical use of receptor-targeted radionuclide therapy, including the practical considerations that accompany it (PMID 31652074), and the resistance review reported that responses can diminish as tumour biology changes (PMID 36551599). Because native somatostatin binds all five receptor subtypes and is cleared from circulation rapidly, reviews of tumour biology have framed broad receptor engagement as a pharmacological limitation of the parent peptide rather than an advantage (PMID 38203605). Readers with clinical questions about somatostatin analogues should raise them with a licensed physician.

Key Takeaways

• Somatostatin works through SSTR1-SSTR5, G protein-coupled receptors that signal mainly through inhibitory G proteins (PMID 20149677).
• The core intracellular events reported are reduced cyclic AMP, increased potassium conductance, reduced calcium entry and phosphatase recruitment (PMID 20149677, PMID 38203605).
• Downstream, reviews describe suppressed pituitary growth hormone release, paracrine inhibition in gut and pancreas, and inhibitory neuromodulation in the brain (PMID 15814848, PMID 32545257, PMID 35204812).
• Receptor expression itself is a variable: regulators such as AIP in pituitary tumours and receptor loss in neuroendocrine tumours alter how strongly the system responds (PMID 28835453, PMID 36551599).

For a broader overview of the peptide, its forms and the research landscape around it, see the somatostatin learn page at /learn/somatostatin/.

References

• Pituitary somatostatin receptor signaling (Trends in Endocrinology and Metabolism, 2010)
• Regulatory Mechanisms of Somatostatin Expression (International Journal of Molecular Sciences, 2020)
• Somatostatin receptors in the brain (Postepy Biochemii, 2018)
• Somatostatin and Somatostatin Receptors in Tumour Biology (International Journal of Molecular Sciences, 2023)
• Role of Somatostatin Signalling in Neuroendocrine Tumours (International Journal of Molecular Sciences, 2022)
• Somatostatin and Somatostatin-Containing Interneurons - From Plasticity to Pathology (Biomolecules, 2022)
• AIP and the somatostatin system in pituitary tumours (The Journal of Endocrinology, 2017)
• Development of growth hormone secretagogues (Endocrine Reviews, 2005)
• (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors (Expert Review of Gastroenterology & Hepatology, 2019)
• Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors (Cancers, 2022)
• Neuropeptide therapeutics to repress lateral septum neurons that disable sociability in an autism mouse model (Cell Reports Medicine, 2024)
• Reduced oxytocin signaling in the dBNST drives the transition from acute pain to persistent anxiety (Current Biology, 2025)